Photobiomodulation Therapy in the Prevention and Treatment of Radiodermatitis in Breast Cancer Patients: Systematic Review Photobiomodulation Therapy and Radiodermatitis.
Journal of Lasers in Medical Sciences,
Vol. 13 (2022),
10 January 2022
,
Page e42
Abstract
Background: Radiodermatitis (RD) is the most common associated effects of radiotherapy, which prevention and treatment has been shown promising results with Photobiomodulation Therapy (PBMT). This study aims to synthesize the evidence about the use of PBMT in management of RD among breast cancer patients undergoing radiotherapy.
Methods: Systematic review with no time restrictions, based on the methodology proposed by the Joanna Briggs Institute (JBI), including the databases PubMed, Cochrane, Web of Science, Scopus and CINAHL. The studies were selected based on inclusion criteria: female participants over 18 years old, with breast cancer and undergoing radiotherapy, using a tridimensional technique or intensity-modulated radiotherapy technique (IMRT). Two reviewers assessed the methodological quality using JBI Critical Appraisal Checklist, and the report was described based on PRISMA.
Results: Red and infrared wavelengths were used. Device power ranged from 1.1 W to 0.08 W for continuous modes and 25 W for pulsed mode, resulting in a 3 and 4 J/cm2 fluence, applied throughout radiotherapy, leading to a reduced severity in cutaneous reactions.
Conclusions: PBMT can reduce radiodermatitis severity. New clinical trials are required for defining protocols, given the scarcity of studies for the adopted site and methodological diversity.
- Radiodermatitis; Photobiomodulation therapy; Breast neoplasms; Radiotherapy.
How to Cite
References
2. Chin V, Nagrial A, Sjoquist K, Chantrill L, Biankin AV, Scholten RJPM, et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database Syst Rev. 2018; 3(3): CD011044. doi: 10.1002/14651858.CD011044
3. Menêses AG, Reis PED, Guerra ENS, Canto GL, Ferreira EB. Use of trolamine to prevent and treat acute radiation dermatitis: a systematic review and meta-analysis. Rev Lat Am Enfermagem. 2018, 26:e2929. doi: 10.1590/1518-8345.2035.2929
4. Spalek M. Chronic radiation-induced dermatitis: challenges and solutions. Clin Cosmet Investig Dermatol. 2016; 9:473-82. doi: 10.2147/CCID.S94320
5. Costa MM. Laser InGaAIP (660nm) in the prevention of radiodermatitis in breast cancer patients undergoing adjuvant radiotherapy [Dissertation]. Vale do Sapucaí University; 2015.
6. Schneider F, Danski MTR, Vayego AS. Usage of Calendula officinalis in the prevention and treatment of radiodermatitis: a randomized double-blind controlled clinical trial. Rev Esc Enferm USP. 2015; 49(2):221-28. doi: 10.1590/S0080-623420150000200006
7. Robijns J, Censabella S, Bulens P, Maes A, Mebis J. The use of low-level light therapy in supportive care for patients with breast cancer: review of the literature. Laser Med Sci. 2017; 32(1): 229-42. doi: 10.1007/s10103-016-2056-y
8. Bensadoun RJ, Nair RG. Low-level laser therapy in the prevention and treatment of cancer therapy-induced mucositis: 2012 state of the art based on literature review and meta-analysis. Curr Opin Oncol. 2012; 24:363–70. doi: 10.1097/CCO.0b013e328352eaa3
9. Wei J, Meng L, Hou X, Qu C, Wang B, Xin Y, et al. Radiation-induced skin reactions: mechanism and treatment. Cancer Manag Res. 2019, 11: 167-177. doi: 10.2147/CMAR.S188655
10. Tufanaru C, Munn Z, Aromataris E, Campbell J, Hopp L. Chapter 3: Systematic reviews of effectiveness. In: Tufanaru C, Munn Z. Joanna Briggs Institute Reviewer’s Manual. Joanna Briggs Institute; 2017.
11. Aromataris E, Munn Z. Chapter 1: JBI Systematic Reviews. In: Aromataris E, Munn Z. Joanna Briggs Institute Reviewer's Manual. Joanna Briggs Institute; 2020. doi: 10.46658/JBIMES-20-02
12. Galvão TF, Pansani TSA, Harrad D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Epidemiol Serv Saude. 2015; 24(2):1-7. doi: 10.5123/S1679-49742015000200017
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009; 6(6): e1000097. doi: 10.1371/journal.pmed1000097
14. Censabella S, Claes S, Robijns J, Pannekoeke L, Bussé L, Colson D et al. Prevention of acute radiodermatitis by photobiomodulation: A randomized, placebo-controlled trial in breast cancer patients (Transdermis Trial). Lasers Surg Med. 2018; 50: 763–71. doi: 10.1002/lsm.22804
15. Robijns J, Censabella S, Claes S, Pannekoeke L, Bussé L, Colson D et al. Biophysical skin measurements to evaluate the effectiveness of photobiomodulation therapy in the prevention of acute radiation dermatitis in breast cancer patients. Support Care Cancer. 2019; 27: 1245–54. doi: 10.1007/s00520-018-4487-4
16. Costa CC, Lyra JS, Nakamura RA, Sousa CM. Radiodermatitis: Analysis of Predictive Factors in Breast Cancer Patients. Rev Bras Cancerol. 2019; 65(1): e-05275. doi: 10.32635/2176-9745.RBC.2019v65n1.275
17. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5): 1341-46. doi: 10.1016/0360-3016(95)00060-C
18. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). National Cancer Institute; 2017.
19. Saad ED, Hoff PM, Carnelos RP, Katz A, Novis YAS, Pietrocola M. Common toxicity criteria of the National Cancer Institute. Rev Bras Cancerol. 2002; 48(1): 63-96.
20. Noble-Adams R. Radiation induced skin reactions: Development of a measurement tool. Brit J Nurs. 1999; 8(18): 1208-11. doi: 10.12968/bjon.1999.8.18.6490
21. Carcano CBM, Oliveira CZ, Paiva BSR, Paiva CE. The Brazilian version of Skindex-16 is a valid and reliable instrument to assess the health-related quality of life of patients with skin diseases. PLoS One. 2018; 13(3): e0194492. doi: 10.1371/journal.pone.0194492
22. Robijns J, Lodewijckxa B, Mebis J, Bensadoun RJ. A narrative review on the use of photobiomodulation therapy for the prevention and management of acute radiodermatitis: proposed mechanisms, current clinical outcomes, and preliminary guidance for clinical studies. Photobiomodul Photomed Laser Surg. 2020; 1-8. doi: 10.1089/photob.2019.4761
23. Kiro NE, Hamblin MR, Abrahamse H. Photobiomodulation of breast and cervical cancer stem cells using low-intensity laser irradiation. Tumor Biology. 2017; 39:1-8. doi: 10.1177/1010428317706913
24. Myakishev-rempel M, Stadler I, Brondon P, Axe D. A preliminary study of the safety of red light phototherapy of tissues harboring cancer. Photomed Laser Surg. 2012; 30(9):551-8. doi: 10.1089/pho.2011.3186
25. Frigo L, Luppi JS, Favero GM, Maria DA, Penna SC, Bjordal JM et al. The effect of low-level laser irradiation (In-Ga-Al-AsP 660 nm) on melanoma in vitro and in vivo. BMC cancer. 2009; 9(404):1-8. doi: 10.1186/1471-2407-9-404
26. Bensadoun RJ, Epstein JB. Photobiomodulation safety in cancer patients: in vivo data. Support Care Cancer. 2020; 1-4. doi: 10.1007/s00520-020-05410-3
27. Barasch A, Li H, Rajasekhar VK, Haimovitz FA, Epstein J, RaberDurlacher J et al. Photobiomodulation effects on head and neck squamous cell carcinoma (HNSCC) in an orthotopic animal model. Support Care Cancer. 2020; 28: 2721–7. doi: 10.1007/s00520-019-05060-0
28. Ottaviani G, Martinelli V, Rupel K, Caronni N, Naseem A, Zandonà L et al. Laser therapy inhibits tumor growth in mice by promoting immune surveillance and vessel normalization. EBioMedicine. 2016; 11: 165–72. doi: 10.1016/j.ebiom.2016.07.028
29. Paglionia MP, Araújo ALD, Arboledaa LPA, Palmiera NR, Fonsêca JM, Silva WG et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities: A systematic review. Oral Oncol. 2019; 93:21–8. doi: 10.1016/j.oraloncology.2019.04.004
30. Elad S, Arany P, Bensadoun RJ, Epstein JB, Barasch A, Raber-Durlacher J. Photobiomodulation therapy in the management of oral mucositis: search for the optimal clinical treatment parameters. Support Care Cancer. 2018; 26(10): 3319-21. doi: 10.1007/s00520-018-4262-6
31. Zecha JA, Raber-durlacher JE, Nair RG, Epstein JB, Sonis ST, Elad S et al. Low-level laser therapy/ photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. Support Care Cancer. 2016; 24(6): 2793–805. doi: 10.1007/s00520-016-3153-y
32. Genot-Klastersky MT, Paesmans M, Ameye L, Kayumba A, Beauvois S, Dragan T et al. Retrospective evaluation of the safety of low-level laser therapy/photobiomodulation in patients with head/neck cancer. Support Care Cancer. 2020; 28(7): 3015-22. doi: 10.1007/s00520-019-05041-3
33. Deng J, Ridner SH, Aulino JM, Murphy BA. Assessment and measurement of head and neck lymphedema: state-of-the-science and future directions. Oral Oncol. 2015; 51: 431-7. doi: 10.1016/j.oraloncology.2015.01.005
34. Bensadoun RJ. Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. Curr Opin Oncol. 2018; 30:1-7. doi: 10.1097/CCO.0000000000000452
35. Deland MM, Weiss RA, Mcdaniel DH, Geronemus RG. Treatment of radiation-induced dermatitis with light-emitting diode (LED) photomodulation. Lasers Surg Med. 2007; 39: 164–8. doi: 10.1002/lsm.20455
36. Fife D, Rayhan DJ, Behnam S, Ortiz A, Elkeeb L, Aquino L et al. A randomized, controlled, double-blind study of light emitting diode photomodulation for the prevention of radiation dermatitis in patients with breast cancer. Dermatol Surg. 2010; 36:1921–7. doi: 10.1111/j.1524-4725.2010.01801.x
37. Strouthos I, Chatzikonstantinou G, Tselis N, Bom D, Karagiannis E, Zoga E et al. Photobiomodulation therapy for the management of radiation-induced dermatitis: a single-institution experience of adjuvant radiotherapy in breast cancer patients after breast conserving surgery. Strahlenth Onkol. 2017; 193:491–8. doi: 10.1007/s00066-017-1117-x
38. Schindl M, Kerschan K, Schindl A, Schon H, Heinzl H, Schindl L. Induction of complete wound healing in recalcitrant ulcers by low-intensity laser irradiation depends on ulcer cause and size. Photodermatol Photoimmunol Photomed. 1999; 15: 18–21. doi: 10.1111/j.1600-0781.1999.tb00047.x
39. Censabella S, Claes S, Robijns J, Bulens P, Mebis J. Photobiomodulation for the management of radiation dermatitis: the DERMIS trial, a pilot study of MLS laser therapy in breast cancer patients. Support Care Cancer. 2016; 24:3925–33. doi: 10.1007/s00520-016-3232-0
40. Rocha BA, Simoes A, Lima LMC, Teixeira MMS, Martinez AS, Melo Filho MS et al. Treating acute cervical radiodermatitis with photobiomodulation therapy: a report of two cases. Photobiomodul Photomed Laser Surg. 2020; 38:19–23. doi: 10.1089/photob.2019.4698
41. Robijns J, Lodewijckx J, Claes S, Pannekoeke L, Censabella S, Bever LV. Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol. 2021; 158:268–75. doi: 10.1016/j.radonc.2021.03.002
42. Singh M, Alavi A, Wong R, Akita S. Radiodermatitis: a review of our current understanding. Am J Clin Dermatol. 2016; 17(3): 277-92. doi: 10.1007/s40257-016-0186-4
- Abstract Viewed: 755 times
- PDF Downloaded: 555 times